These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 29747337)
21. Cost-effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial. Cromwell I; Smith LW; van der Hoek K; Hedden L; Coldman AJ; Cook D; Franco EL; Krajden M; Martin R; Lee MH; Stuart G; van Niekerk D; Ogilvie G; Peacock S Cancer Med; 2021 May; 10(9):2996-3003. PubMed ID: 33811457 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of p16/Ki-67 dual staining in the detection of cervical precancer and cancer in China. Zhang SK; Jia MM; Zhao DM; Wu ZN; Guo Z; Liu YL; Guo PP; Chen Q; Cao XQ; Liu SZ; Chen W; Sun XB Cancer Epidemiol; 2019 Apr; 59():123-128. PubMed ID: 30739069 [TBL] [Abstract][Full Text] [Related]
23. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort. Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754 [TBL] [Abstract][Full Text] [Related]
24. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N; J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502 [TBL] [Abstract][Full Text] [Related]
25. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program. Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376 [TBL] [Abstract][Full Text] [Related]
26. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs. Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541 [TBL] [Abstract][Full Text] [Related]
27. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial. Cook DA; Mei W; Smith LW; van Niekerk DJ; Ceballos K; Franco EL; Coldman AJ; Ogilvie GS; Krajden M BMC Cancer; 2015 Dec; 15():968. PubMed ID: 26674353 [TBL] [Abstract][Full Text] [Related]
28. Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China. Pan QJ; Hu SY; Zhang X; Ci PW; Zhang WH; Guo HQ; Cao J; Zhao FH; Lytwyn A; Qiao YL Cancer Cytopathol; 2013 Sep; 121(9):473-82. PubMed ID: 23907807 [TBL] [Abstract][Full Text] [Related]
29. Clinical evaluation of p16 Rezhake R; Wang Y; Chen F; Hu SY; Zhang X; Cao J; Qiao YL; Zhao FH; Arbyn M Cancer Cytopathol; 2021 Sep; 129(9):679-692. PubMed ID: 33826790 [TBL] [Abstract][Full Text] [Related]
30. Age-specific effectiveness of primary human papillomavirus screening versus cytology in a cervical cancer screening program: a nationwide cross-sectional study. Bao H; Ma L; Zhao Y; Song B; Di J; Wang L; Gao Y; Ren W; Wang S; Wu J; Wang HJ Cancer Commun (Lond); 2022 Mar; 42(3):191-204. PubMed ID: 35142100 [TBL] [Abstract][Full Text] [Related]
31. Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening. Hesselink AT; Sahli R; Berkhof J; Snijders PJ; van der Salm ML; Agard D; Bleeker MC; Heideman DA J Clin Virol; 2016 Mar; 76():36-9. PubMed ID: 26809131 [TBL] [Abstract][Full Text] [Related]
32. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Whitlock EP; Vesco KK; Eder M; Lin JS; Senger CA; Burda BU Ann Intern Med; 2011 Nov; 155(10):687-97, W214-5. PubMed ID: 22006930 [TBL] [Abstract][Full Text] [Related]
33. HPV-negative high-grade cervical precancerous lesions or invasive cancer in China: A post hoc analysis of a multicentric clinical study. Bao H; Zhao Y; Zhang X; Bi H; Cong S; Fang L; Wang HJ; Wang L Int J Gynaecol Obstet; 2023 Apr; 161(1):159-167. PubMed ID: 36444986 [TBL] [Abstract][Full Text] [Related]
34. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia. Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658 [TBL] [Abstract][Full Text] [Related]
35. Triage Value of Cervical Exfoliated Cell DNA Ploidy Analysis in Cervical High-Risk Human Papillomavirus-Positive Women. Chu B; Dong J; Chen Y; Ru X; Zhang W; Chen Y; Zhang X; Cheng X J Low Genit Tract Dis; 2023 Oct; 27(4):331-336. PubMed ID: 37589311 [TBL] [Abstract][Full Text] [Related]
36. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico. Torres-Ibarra L; Cuzick J; Lorincz AT; Spiegelman D; Lazcano-Ponce E; Franco EL; Moscicki AB; Mahmud SM; Wheeler CM; Rivera-Paredez B; Hernández-López R; León-Maldonado L; Salmerón J; JAMA Netw Open; 2019 Nov; 2(11):e1915781. PubMed ID: 31747033 [TBL] [Abstract][Full Text] [Related]
37. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial. Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397 [TBL] [Abstract][Full Text] [Related]
38. Cervical cancer screening cotesting with cytology and MRNA HPV E6/E7 yields high rates of CIN2+ lesions in young women. Granados R; Tellez-Safina H; Solis I; Mateos F; Rodriguez-Barbero JM; Aramburu JA; Huertas MA; Bajo P; Camarmo E; Corrales T; Medina P; Calvo B; Martin E; Anta L; Zamora M; Alcaide T Diagn Cytopathol; 2017 Dec; 45(12):1065-1072. PubMed ID: 28949442 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Ghiringhello B; Girlando S; Gillio-Tos A; De Marco L; Naldoni C; Pierotti P; Rizzolo R; Schincaglia P; Zorzi M; Zappa M; Segnan N; Cuzick J; Lancet Oncol; 2010 Mar; 11(3):249-57. PubMed ID: 20089449 [TBL] [Abstract][Full Text] [Related]
40. An economic evaluation of two cervical screening algorithms in Belgium: HR-HPV primary compared to HR-HPV and liquid-based cytology co-testing. Dombrowski C; Bourgain C; Ma Y; Meiwald A; Pinsent A; Weynand B; Turner KME; Huntington S; Adams EJ; Bogers J; Croes R; Sahebali S Eur J Cancer Prev; 2024 May; 33(3):262-270. PubMed ID: 37933867 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]